MedTrace Logo

A Phase Ib/II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG

NCT04270838 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2025-11-18

No results posted yet for this study

Summary

This is a Phase Ib/II, open-label, head-to-head, age de-escalation dose-escalation, partially randomized trial to study the safety and immunogenicity of the candidate rabies vaccine ChAdOx2 RabG in healthy adults (age 18-45 years) and young children (age 2-6 years). ChAdOx2 RabG will be administered intramuscularly and licensed rabies vaccine will be given by intradermal injection.

Conditions

  • Rabies

Interventions

BIOLOGICAL

ChAdOx2 RabG

Single dose of ChAdOx2 RabG at different concentrations: 1x10\^10 and 5x10\^10

BIOLOGICAL

Inactivated Rabies Vaccine

A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units

Sponsors & Collaborators

  • Ifakara Health Institute

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Alexander D Douglas · Jenner Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
2 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-17
Primary Completion
2028-09-30
Completion
2028-09-30

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04270838 on ClinicalTrials.gov